StockData
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp. (BCTX) stock

BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 28, 2026Score 4/30
$3.51+0.21 (+6.36%)

Close on Nov 17, 2026Market cap $30.65MP/E –Yield –

BriaCell Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

BriaCell Therapeutics's operating cash flow for the twelve months ending Jul 31, 2026 was -$28.65M. For fiscal 2026 it was -$28.65M. The highest annual figure on record is -$1.27M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2026Jul 31, 2026-$28.65M–
FY2025Jul 31, 2025-$28.17M–
FY2024Jul 31, 2024-$24.13M–
FY2023Jul 31, 2023-$23.74M–
FY2022Jul 31, 2022-$12.48M–
FY2021Jul 31, 2021-$7.75M–
FY2020Jul 31, 2020-$1.27M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jul 31, 2026-$5.96M–
Q3 FY2026CQ1 2026Apr 30, 2026-$7.02M–
Q2 FY2026CQ4 2025Jan 31, 2026-$7.97M–
Q1 FY2026CQ3 2025Oct 31, 2025-$7.70M–
Q4 FY2025CQ2 2025Jul 31, 2025-$8.13M–
Q3 FY2025CQ1 2025Apr 30, 2025-$7.16M–
Q2 FY2025CQ4 2024Jan 31, 2025-$5.92M–
Q1 FY2025CQ3 2024Oct 31, 2024-$6.96M–
Q4 FY2024CQ2 2024Jul 31, 2024-$4.04M–
Q3 FY2024CQ1 2024Apr 30, 2024-$5.08M–
Q2 FY2024CQ4 2023Jan 31, 2024-$7.40M–
Q1 FY2024CQ3 2023Oct 31, 2023-$7.61M–
Q4 FY2023CQ2 2023Jul 31, 2023-$10.92M–
Q3 FY2023CQ1 2023Apr 30, 2023-$5.33M–
Q2 FY2023CQ4 2022Jan 31, 2023-$3.95M–
Q1 FY2023CQ3 2022Oct 31, 2022-$3.54M–
Q4 FY2022CQ2 2022Jul 31, 2022-$3.33M–
Q3 FY2022CQ1 2022Apr 30, 2022-$4.82M–
Q2 FY2022CQ4 2021Jan 31, 2022-$2.56M–
Q1 FY2022CQ3 2021Oct 31, 2021-$1.78M–
Q4 FY2021CQ2 2021Jul 31, 2021-$1.95M–
Q3 FY2021CQ1 2021Apr 30, 2021-$5.59M–

More BriaCell Therapeutics figures

See a number that looks wrong?